<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04399642</url>
  </required_header>
  <id_info>
    <org_study_id>Single-Dose</org_study_id>
    <nct_id>NCT04399642</nct_id>
  </id_info>
  <brief_title>Intra-articular Vancomycin Powder in Knee and Hip Arthroplasty</brief_title>
  <official_title>Intra-articular Vancomycin Powder in Knee and Hip Arthroplasty: a Prospective, Randomized Clinical Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare infection rates when patients, elected for primary or
      aseptic revision THA / TKA, have a single intravenous antibiotic dose versus one single
      intravenous antibiotic dose in combination with intra-articular antibiotics. This is a
      prospective, randomized clinical survey on selected outcome measurements on 1834 subjects who
      will be recruited in a period of about 2 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group A: patients receiving single dose of IV cefazolin 10-60 minutes before incision.

      Group B: patients receiving a single dose of IV cefazolin 10-60 minutes before incision + a
      single dose of intra-articular vancomycin powder before articulation (hip or knee) closure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Because of the nature of the intervention, it is impossible for the surgeon to be blinded. However, postoperative infection will be diagnosed by an independent co-worker, not involved in the surgery. Patients will be blind as they will not be aware if they had intra-articular vancomycin powder or not</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Infection rate</measure>
    <time_frame>3 months</time_frame>
    <description>Infection rate after after lowerlimb arthroplasty depending on the antibiotic molecule that was given</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term infection rate</measure>
    <time_frame>2 years</time_frame>
    <description>Infection rate after after lowerlimb arthroplasty depending on the antibiotic molecule that was given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factor</measure>
    <time_frame>2 years</time_frame>
    <description>Infection rate in patients with risk factors depending on the antibiotic molecule that was given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary vs revision</measure>
    <time_frame>2 years</time_frame>
    <description>Infection rate in primary versus revisions surgery depending on the antibiotic molecule that was given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery time</measure>
    <time_frame>2 years</time_frame>
    <description>Infection rate according to surgery time depending on the antibiotic molecule that was given</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Western Ontario and McMaster Universities Arthritis Index (WOMAC)</measure>
    <time_frame>baseline, 1 year</time_frame>
    <description>Scale from 0 to 97. 97 indicate worse pain, stiffness, and functional limitations</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>baseline, 1 year</time_frame>
    <description>The descriptive system section of the EQ-5D questionnaire produces a 5-digit health state profile that represents the level of reported problems on each of the five dimensions of health</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1832</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving single dose of IV cefazolin (2 grams if &lt; 120kg; 3 grams if &gt;120kg) 10-60 minutes before incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vanco</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving a single dose of IV cefazolin (2 grams if &lt; 120kg; 3 grams if &gt;120kg) 10-60 minutes before incision + a single dose of intra-articular vancomycin powder (1 gram) before articulation (hip or knee) closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arthroplasty</intervention_name>
    <description>All patients include in the study will undergo a lowerlimb arthroplasty, primary or revision</description>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_label>Vanco</arm_group_label>
    <other_name>Knee arthroplasty</other_name>
    <other_name>Hip arthroplasty</other_name>
    <other_name>Knee aseptic revision arthroplasty</other_name>
    <other_name>Hip arthroplaty revision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Standard criteria for the implantation of primary total hip or knee replacement

          -  Revision of an aseptic THA or TKA.

          -  Adults &gt;18 years of age

          -  Diagnosis of Osteoarthrosis (OA), Osteonecrosis (ON), Arthritis; or aseptic loosening
             of THA/TKA.

          -  Subject is willing to consent to participate in the study

          -  Subject is available for follow-up through at least 2 years

          -  Subject has met acceptable preoperative medical clearance and is free of or treated
             for medical conditions that would pose excessive operative risk.

          -  Subject who are fluent in English and / or French and able to understand their role in
             the study

        Exclusion Criteria:

          -  Active, local infection or systemic infection.

          -  Participation in any other pharmaceutical, biologic or medical device clinical
             investigation

          -  Subjects with known allergy to vancomycin

          -  Subjects unable to consent

          -  Patient with skin pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Benoit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSS du Nord de l'Île de Montreal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit Benoit, MD</last_name>
    <phone>514-338-2222</phone>
    <phone_ext>2050</phone_ext>
    <email>ben1000ben@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karine Tardif</last_name>
    <phone>514-338-2222</phone>
    <phone_ext>3465</phone_ext>
    <email>karinetardif2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Sacré-Coeur de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit Benoit, MD</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>2050</phone_ext>
      <email>ben1000ben@icloud.com</email>
    </contact>
    <contact_backup>
      <last_name>Karine Tardif</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>3465</phone_ext>
      <email>karinetardif2@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal</investigator_affiliation>
    <investigator_full_name>Benoit Benoit</investigator_full_name>
    <investigator_title>Orthopaedic surgeon, principal investigator</investigator_title>
  </responsible_party>
  <keyword>vancomycine</keyword>
  <keyword>hip arthroplasty</keyword>
  <keyword>knee arthroplasty</keyword>
  <keyword>hip revision arthroplasty</keyword>
  <keyword>knee revision arthroplasty</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

